myChoice HRD is a tumor test that can help guide important PARP inhibitor therapy decisions

About myChoice HRD

myChoice HRD identifies patients that are most likely to benefit from PARP inhibitors. Every patient’s cancer is unique, so their treatment should be as well. Myriad’s myChoice HRD helps physicians select the most effective treatment for their patients, minimizing the time and toxicity associated with ineffective therapies.

Learn More

Identify More Patients

Identify More Hope

myChoice HRD’s unique phenotypic approach identifies more patients who are more likely to preferentially benefit from PARP inhibitors than BRCA testing alone.

Recommended Links